A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics
of SC0062 capsule in patients with chronic kidney disease (diabetic kidney disease and IgA
nephropathy)with albuminuria compared to matching placebo.